SCHEMBL3889758

SCHEMBL3889758

CNS(=O)(=O)c1ccc2cc(-c3cc(CCC(=O)OC)ccc3OCC3CCCC3)ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.40
SRC P12931 2/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 4/20 0.37
CTSD P07339 3/20 0.37
PTPN1 P18031 1/20 0.37
GAA P10253 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
C5AR1 P21730 1/20 0.36
CCR9 P51686 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
RORC P51449 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881625 0.92 FFAR4 (0.43) BRD4SRCKMT2AMEN1ALDH1A1
SCHEMBL3884475 0.91 BRD4 (0.46) BRD4KMT2AMEN1PTPN1
SCHEMBL3885425 0.90 IKBKB (0.40) BRD4SRCKMT2AMEN1CTSD
SCHEMBL3884610 0.89 ALDH1A1 (0.43) BRD4SRCKMT2AMEN1ALDH1A1
SCHEMBL3887867 0.88 C5AR1 (0.42) SRCKMT2AMEN1ALDH1A1PTPN1
SCHEMBL3883719 0.86 CCNC (0.48) SRCKMT2AMEN1PTPN1LMNA
SCHEMBL3676519 0.86 C5AR1 (0.40) BRD4SRCKMT2AMEN1PTPN1
SCHEMBL3681581 0.86 MEN1 (0.41) SRCKMT2AMEN1ALDH1A1PTPN1
SCHEMBL3680727 0.85 C5AR1 (0.41) SRCKMT2AMEN1ALDH1A1PTPN1
SCHEMBL3887753 0.85 MEN1 (0.42) SRCKMT2AMEN1ALDH1A1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 BRD4 1440/4885SRC 3603/4885KMT2A 2392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.